Moberg Pharma AB (Formerly known as Moberg Derma) And Colep Enters Development Agreement For Late-Stage Development Of MOB-015

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (STO:MOB) today announced that Moberg Pharma and Colep – a leading global player in the consumer goods packaging and contract manufacturing industries – entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).

Help employers find you! Check out all the jobs and post your resume.